Compare Stocks: PLRX, ARTV, BBOT, and PLX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$4.27 -30.7%	$8.55	$2.96 ▼ $14.53	N/A	N/A	N/A	8.65 million shs
BBOT BridgeBio Oncology Therapeutics	$2.69 +1.9%	$5.39	$2.51 ▼ $14.87	$211.66M	0.65	N/A	1.76 million shs
PLRX Pliant Therapeutics	$0.86 +0.9%	$1.06	$0.83 ▼ $1.83	$52.62M	1.27	N/A	346,676 shs
PLX Protalix BioTherapeutics	$2.53 +2.0%	$2.63	$1.65 ▼ $3.19	$199.82M	-0.09	905,776 shs	448,303 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	-30.68%	-34.91%	-38.91%	-57.28%	-15.28%
BBOT BridgeBio Oncology Therapeutics	+1.89%	-1.10%	-31.90%	-67.31%	+268,999,900.00%
PLRX Pliant Therapeutics	+0.86%	-6.06%	-20.64%	-18.37%	-52.38%
PLX Protalix BioTherapeutics	+2.02%	-4.17%	-6.99%	+11.45%	+6.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$4.27 -30.7%	$8.55	$2.96 ▼ $14.53	N/A	N/A	N/A	8.65 million shs
BBOT BridgeBio Oncology Therapeutics	$2.69 +1.9%	$5.39	$2.51 ▼ $14.87	$211.66M	0.65	N/A	1.76 million shs
PLRX Pliant Therapeutics	$0.86 +0.9%	$1.06	$0.83 ▼ $1.83	$52.62M	1.27	N/A	346,676 shs
PLX Protalix BioTherapeutics	$2.53 +2.0%	$2.63	$1.65 ▼ $3.19	$199.82M	-0.09	905,776 shs	448,303 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	-30.68%	-34.91%	-38.91%	-57.28%	-15.28%
BBOT BridgeBio Oncology Therapeutics	+1.89%	-1.10%	-31.90%	-67.31%	+268,999,900.00%
PLRX Pliant Therapeutics	+0.86%	-6.06%	-20.64%	-18.37%	-52.38%
PLX Protalix BioTherapeutics	+2.02%	-4.17%	-6.99%	+11.45%	+6.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	2.43	Hold	$30.00	602.58% Upside
BBOT BridgeBio Oncology Therapeutics	2.82	Moderate Buy	$21.11	684.80% Upside
PLRX Pliant Therapeutics	2.00	Hold	$3.00	250.02% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$12.00	374.31% Upside

Current Analyst Ratings Breakdown

Latest PLRX, ARTV, BBOT, and PLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/27/2026	ARTV Artiva Biotherapeutics	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold
10/27/2026	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold
10/27/2026	ARTV Artiva Biotherapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Neutral	$4.00
10/21/2026	BBOT BridgeBio Oncology Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$13.00
10/20/2026	BBOT BridgeBio Oncology Therapeutics	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$16.00
10/19/2026	ARTV Artiva Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	PLRX Pliant Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/9/2026	BBOT BridgeBio Oncology Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/2/2026	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/2/2026	ARTV Artiva Biotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$40.00
9/14/2026	BBOT BridgeBio Oncology Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 10/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A	N/A
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	$80.62M	2.53	$0.14 per share	17.80	$0.47 per share	5.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	N/A	-$3.30	N/A	N/A	N/A	N/A	N/A	N/A	11/11/2026 (Estimated)
BBOT BridgeBio Oncology Therapeutics	N/A	-$2.76	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	-$1.49	N/A	N/A	N/A	N/A	N/A	N/A	11/5/2026 (Estimated)
PLX Protalix BioTherapeutics	$8.31M	$0.23	N/A	8.16	N/A	-21.03%	-30.89%	-11.74%	N/A

Latest PLRX, ARTV, BBOT, and PLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ARTV Artiva Biotherapeutics	-$0.54	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	PLRX Pliant Therapeutics	-$0.37	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	BBOT BridgeBio Oncology Therapeutics	N/A	-$705.20	N/A	-$705.20	N/A	N/A
8/11/2026	Q2 2026	PLRX Pliant Therapeutics	-$0.3418	-$0.36	-$0.0182	-$0.36	N/A	N/A
8/6/2026	Q2 2026	ARTV Artiva Biotherapeutics	-$0.6251	-$0.63	-$0.0049	-$0.63	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	N/A	N/A
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	1.98	1.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
BBOT BridgeBio Oncology Therapeutics	54.89%
PLRX Pliant Therapeutics	97.30%
PLX Protalix BioTherapeutics	16.53%

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	1.80%
BBOT BridgeBio Oncology Therapeutics	24.40%
PLRX Pliant Therapeutics	8.74%
PLX Protalix BioTherapeutics	6.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	115	N/A	48.01 million	Optionable
BBOT BridgeBio Oncology Therapeutics	88	80.17 million	60.61 million	N/A
PLRX Pliant Therapeutics	49	61.92 million	56.51 million	Optionable
PLX Protalix BioTherapeutics	226	80.57 million	69.00 million	Optionable

PLRX, ARTV, BBOT, and PLX Headlines

Recent News About These Companies

Protalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16, 2026 | seekingalpha.com

Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences

September 8, 2026 | prnewswire.com

Protalix (PLX) Q2 2026 Earnings Call Transcript

August 19, 2026 | finance.yahoo.com

Protalix BioTherapeutics (NYSEAMERICAN:PLX) Advances Plant-Cell Protein Programs

August 16, 2026 | kalkinemedia.comK

PLX: Elfabrio estimates up

August 13, 2026 | msn.com

Protalix signals Elfabrio path to 15% to 20% Fabry market share by 2031, backed by Europe every-4-weeks approval

August 12, 2026 | seekingalpha.com

Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript

August 12, 2026 | seekingalpha.com

Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

August 12, 2026 | finanznachrichten.de

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

August 12, 2026 | prnewswire.com

Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

August 5, 2026 | prnewswire.com

Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary

May 15, 2026 | finance.yahoo.com

PLX: Chiesi Milestone Received

May 14, 2026 | finance.yahoo.com

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2026 Earnings Call Transcript

May 14, 2026 | insidermonkey.com

Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call

May 14, 2026 | uk.finance.yahoo.com

Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...

May 14, 2026 | finance.yahoo.com

Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript

May 13, 2026 | seekingalpha.com

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

May 13, 2026 | prnewswire.com

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

May 6, 2026 | prnewswire.com

Protalix: Elfabrio Struggles Against Oral Competition

April 15, 2026 | seekingalpha.com

Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance

March 24, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PLRX, ARTV, BBOT, and PLX Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$4.27 -1.89 (-30.68%)

Closing price 10/27/2026 04:00 PM Eastern

Extended Trading

$4.16 -0.11 (-2.69%)

As of 04:01 AM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

BridgeBio Oncology Therapeutics NASDAQ:BBOT

$2.69 +0.05 (+1.89%)

Closing price 10/27/2026 04:00 PM Eastern

Extended Trading

$2.69 0.00 (0.00%)

As of 04:38 AM Eastern

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor is an affiliate of Cormorant, a leading life sciences focused investment firm with over $2 billion in assets under management as of December 31, 2022. Our Chairperson and Chief Executive Officer, Bihua Chen, founded Cormorant and is the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.

Pliant Therapeutics NASDAQ:PLRX

$0.86 +0.01 (+0.86%)

Closing price 10/27/2026 04:00 PM Eastern

Extended Trading

$0.86 0.00 (-0.01%)

As of 10/27/2026 07:55 PM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Protalix BioTherapeutics NYSE:PLX

$2.53 +0.05 (+2.02%)

Closing price 10/27/2026 04:00 PM Eastern

Extended Trading

$2.47 -0.06 (-2.41%)

As of 04:24 AM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLRX, ARTV, BBOT, and PLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLRX, ARTV, BBOT, and PLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLRX, ARTV, BBOT, and PLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PLRX, ARTV, BBOT, and PLX Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Pliant Therapeutics NASDAQ:PLRX

Protalix BioTherapeutics NYSE:PLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLRX, ARTV, BBOT, and PLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLRX, ARTV, BBOT, and PLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLRX, ARTV, BBOT, and PLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PLRX, ARTV, BBOT, and PLX Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Pliant Therapeutics NASDAQ:PLRX

Protalix BioTherapeutics NYSE:PLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools